{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:vericiguat",
  "owner": "cardio",
  "kind": "drug",
  "slug": "vericiguat",
  "name": "Vericiguat",
  "aliases": [
    "Verquvo"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Vericiguat, sold as Verquvo, is a soluble guanylate cyclase stimulator, a medicine taken by mouth. The US label read lists one use in adults: to reduce the risk of cardiovascular death and hospitalization for heart failure after a hospitalization for heart failure or the need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction below 45%. The label carries a boxed warning for embryo-fetal toxicity, which concerns the unborn child and is recorded separately.",
  "summary_technical": "RxNorm ingredient 2475830; UNII LV66ADM269. MeSH has no descriptor for vericiguat (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Soluble Guanylate Cyclase Stimulator. The record is filed under the class page for soluble guanylate cyclase stimulators on that evidence. The label read is the Merck Sharp & Dohme LLC label for Verquvo, application NDA214377, effective 2026-01-21 in openFDA. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the title and one sentence of the boxed warning, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "2475830",
      "normalized_value": "2475830",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "LV66ADM269",
      "normalized_value": "LV66ADM269",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart"
      ],
      "condition-area": [
        "heart-failure"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says vericiguat stimulates soluble guanylate cyclase, an enzyme in the nitric oxide signaling pathway."
  },
  "content_digest": "c94c5f6dba6a2a04cc230cfb0dc7e3800a84311a848d2060d0b3f04fbf69fab8",
  "review": {
    "content_digest": "c94c5f6dba6a2a04cc230cfb0dc7e3800a84311a848d2060d0b3f04fbf69fab8",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-vericiguat-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:vericiguat",
      "category": "descriptive",
      "statement": "The US label of Verquvo (vericiguat tablets, Merck Sharp & Dohme LLC, application NDA214377; the version dated 2026-01-21 in openFDA) describes vericiguat as a soluble guanylate cyclase stimulator. It lists reducing the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.",
      "context": {
        "id": "cardio:ctx-fda-verquvo-label-us",
        "label": "Adults with symptomatic chronic heart failure and an ejection fraction below 45%, as described in the US label of Verquvo",
        "recipient": "adult",
        "population": "Adults with symptomatic chronic heart failure and an ejection fraction less than 45%, following a hospitalization for heart failure or the need for outpatient intravenous diuretics, as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with symptomatic chronic heart failure and ejection fraction less than 45%",
            "Following a hospitalization for heart failure or need for outpatient intravenous diuretics"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The boxed warning is in a separate claim about the fetus. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, second sentence",
          "applicability_note": "Label passage quoted in the research quote table (LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-verquvo-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:14Z",
            "content_hash": "efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-verquvo",
            "source_type": "regulator",
            "title": "openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-vericiguat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (LB-05, LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-verquvo-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:14Z",
            "content_hash": "efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-verquvo",
            "source_type": "regulator",
            "title": "openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-vericiguat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260121.",
          "snapshot": {
            "id": "cardio:openfda-label-verquvo-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:14Z",
            "content_hash": "efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-verquvo",
            "source_type": "regulator",
            "title": "openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-vericiguat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "a1e11aaaadb1da84aa9e47e0710bed019607d244f1396af9170a579546babe85",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-vericiguat-label-indications.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-verquvo-label-boxed-warning",
      "owner": "cardio",
      "subject_entity_id": "cardio:vericiguat",
      "category": "safety",
      "statement": "The same US label of Verquvo carries a boxed warning titled embryo-fetal toxicity. It says the medicine may cause fetal harm.",
      "context": {
        "id": "cardio:ctx-fda-verquvo-label-fetal-risk",
        "label": "The developing fetus, for a person taking vericiguat during pregnancy, as described in a US label boxed warning",
        "recipient": "fetal",
        "population": "The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Fetus during pregnancy; the passage read gives no gestational ages",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Pregnancy during which the medicine is taken (risk to the fetus)"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], title",
          "applicability_note": "Label passage quoted in the research quote table (LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-verquvo-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:14Z",
            "content_hash": "efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-verquvo",
            "source_type": "regulator",
            "title": "openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-vericiguat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], first paragraph",
          "applicability_note": "Label passage quoted in the research quote table (LB-08).",
          "snapshot": {
            "id": "cardio:openfda-label-verquvo-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:14Z",
            "content_hash": "efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-verquvo",
            "source_type": "regulator",
            "title": "openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-vericiguat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260121.",
          "snapshot": {
            "id": "cardio:openfda-label-verquvo-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:14Z",
            "content_hash": "efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb",
            "source_effective_date": "2026-01-21",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-verquvo",
            "source_type": "regulator",
            "title": "openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%2217056d73-1b1b-4bf2-9c07-b7a9367f0d6d%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-vericiguat.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "09f93899b8a888e2be94adccdea63956383eb2577e43ebab3fde17a9f3ed5999",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-verquvo-label-boxed-warning.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists reducing the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and an ejection fraction less than 45% as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:heart-failure",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-vericiguat-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "The FDA established pharmacologic class of vericiguat in RxClass is Soluble Guanylate Cyclase Stimulator",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:soluble-guanylate-cyclase-stimulators",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-2475830-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/vericiguat/",
  "context_path": "api/v1/context/cardio--vericiguat.md"
}
